FDA Grants QIDP Designation to Kinnear Pharma for treatment of Acinetobacter baumannii Infections
FDA QiDP designation is the 4th issued to Kinnear establishing Kinnear as a leader in the fight against antimicrobial resistance (AMR). PARK CITY, UTAH, UNITED STATES, July 23, 2024 /EINPresswire.com/ -- Kinnear Pharmaceuticals, LLC and Kinnear Pharma …